SynthesisTranslational psychiatry2026
The relationship between renin-angiotensin system-modulating medication and depression: a systematic review.
Synthesis in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe renin-angiotensin system (RAS) is implicated in stress, inflammation, and reward-related neurobiology, and RAS inhibition shows antidepressant-like effects in preclinical models. Whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are associated with depression outcomes in adults remains uncertain.
methodsWe searched MEDLINE, Embase, PsycINFO, APA PsycArticles, and AMED from inception to November 2024 for observational studies examining ACEI or ARB exposure and depression outcomes in adults. Risk of bias was assessed with the Quality in Prognosis Studies (QUIPS) tool. Due to methodological heterogeneity, no meta-analysis was performed, and findings were synthesised using structured direction of effect methods, with sensitivity synthesis restricted to studies at low risk of confounding.
resultsFifteen studies involving more than 7 million participants were included. Eight studies reported protective associations between ACEI or ARB exposure and depression outcomes, six found no clear association, and one linked data cohort reported a modest increase in major depressive disorder with angiotensin antagonist monotherapy compared with patients not receiving antihypertensive treatment. Protective associations were more common in large registry cohorts using clinician-coded outcomes, whereas studies using symptom scales or prescription-based proxies were more often null. Among studies with stronger confounding control, findings were mixed.
conclusionObservational evidence suggests a modest protective association between ACEI or ARB exposure and depression outcomes. However, heterogeneity in exposure and outcome definitions, together with residual confounding, limits causal inference. Prospective studies using bias-resistant designs and improved characterisation of incident depression, and better characterisation of drug-specific exposure are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.